Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS.

By H. Maeda, T. Sawa, T. Konno. Journal of Controlled Release, 2001

879 citations recorded by the source corpus.

Subfields: Biomaterials, Biomedical Engineering, Materials Chemistry

View Paper: https://www.semanticscholar.org/paper/a73feadb9f6b748679cb43f664b99d3023ca62e8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

In Biomedical Engineering

In Materials Chemistry

Citations in the corpus

Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential (2006, background): “By the same token, an inverse relationship has been observed between dose and magnitude of the ABC effect.”
A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. (2011, background): “found that high-molecular-weight (40 kDa or higher), long-circulating macromolecules as well as various long-circulating nanoparticulate pharmaceutical carriers are capable of spontaneously accumulating in various pathological sites, such as solid tumours and infracted areas, via the so-called ‘enha”
Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. (2013, methodology): “The earliest example was generated by the Maeda group [2, 61-63] : a styrene maleic anhydride polymer was conjugated to neocarzinostatin (SMANCS), and patients treated with this therapeutic were imaged by CT, with tumor accumulation of the therapy reading 10-200 times higher than normal tissues.”
Silver nanoparticles: Synthesis, medical applications and biosafety (2020, background): “Due to the enhanced permeability and retention (EPR) effect, tumor cells preferentially absorb NPs-sized bodies than normal tissues [33, 34].”
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come (2016, background): “Consequently, any nanoparticles entering tumors are not efficiently removed by the lymphatic system, causing nanoparticle accumulation within the tumor (Maeda et al., 2001; Maeda et al., 2009).”
Micellar Nanocarriers: Pharmaceutical Perspectives (2006, background): “ity of a particulate drug carrier in the circulation and its ability to reach its target site have been observed on multiple occasions (32,160).”